NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: NeonDrum Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

More Part-time Chemistry Degrees Needed Says Melbourn Scientific CEO - New award at DDL22 recognises the contribution of young people to the pharmaceutical industry - MelbournScientific.com
More Part-time Chemistry Degrees Needed Says Melbourn Scientific CEO

 

NewswireTODAY - /newswire/ - Cambridge, United Kingdom, 2011/09/20 - New award at DDL22 recognises the contribution of young people to the pharmaceutical industry - MelbournScientific.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Analytical chemistry is a field of science where practical laboratory experience during a degree is invaluable. To encourage young people the aerosol industry conference ‘Drug Delivery to the Lung’, now in its 22nd year, has introduced an award for “those who do the research, not their stuffy old boss or academic supervisor”.

Mark Hammond, CEO of Melbourn Scientific and a member of the organising committee, believes that one of DDL’s strengths is its inclusive ethos and would like to see more opportunities for school leavers to take part-time degree courses.

He says: “DDL is a genuine meeting of minds and covers all aspects of the inhaled device development from the latest drugs to the plastics that are used in inhaler manufacture. It is very fitting that there will be a ‘New Investigator’ award introduced this year in memory of Pat Burnell, who sadly passed away last year. It is aimed at encouraging young researchers to present their work at DDL and this is something she actively promoted.”

Melbourn Scientific is a gold sponsor of DDL and the company has a strong policy of growing young talent through its excellent in-house training. This broadens the capabilities of their workforce and allows scientists to be trained to have exactly the right techniques.

In the past, employees have been able to study part time, either for a chemistry or business-related degree. However, part-time study for science degrees in particular at universities has become less common and there are fewer opportunities for this route to be taken.

Mark Hammond says: “I studied for my Chemistry degree part-time and I think for a practical subject such as science this has many advantages both to the student and the employer. I hope that the increase in tuition fees and the current focus on apprenticeships will encourage universities to rethink their strategies on part time education.”

Melbourn Scientific also works with undergraduates from a selection of universities, taking them on for 6-10 week projects, either in the office for students on an entrepreneurship course or in the lab for chemistry students.

The DDL Organising Committee introduced the award in honour of Dr Patricia (‘Pat’) KP Burnell, and it will be presented annually. Pat was a key instigator for the DDL conference and her vision was for a conference that is accessible and inclusive to all. She was passionate about aerosol science and this award recognises Pat’s contribution to the science.

Melbourn Scientific, a leading provider of analytical and formulation support for the pharma and biotech industries, is based near Cambridge, UK and employs 75 staff members.

For media enquiries contact: Rachel Holdsworth/Rebecca Nesbit - T: 01954 202789

Melbourn Scientific:
Martin Westcott,
Business Development Manager,
Melbourn Scientific Ltd,
T: 01763 261648

About Melbourn Scientific
Melbourn Scientific (melbournscientific.com), based near Cambridge UK, provides high quality analytical and formulation services to the pharmaceutical and healthcare industry. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies.

Melbourn Scientific has invested continually in the latest equipment and provides a range of services; formulation and product development; method development and analytical support; stability studies and storage; accelerated feasibility studies, GMP facilities and manufacturing

Distributed by NeonDrum.com news distribution service on behalf of Holdsworth Associates.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: NeonDrum Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


More Part-time Chemistry Degrees Needed Says Melbourn Scientific CEO

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Liz Hartney - NeonDrum.com 
+44(0)75 1051 8732 news[.]neondrum.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NeonDrum Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NeonDrum Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit Enciris Technologies

Visit  JobsWare.com





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)